CSPC Pharmaceutical Group Expands Subsidiary Operations in China

Reuters
24 Jun
CSPC Pharmaceutical Group Expands Subsidiary Operations in China

CSPC Pharmaceutical Group Ltd., a leading entity in the pharmaceutical industry, has several key subsidiaries actively engaged in the manufacturing and sales of pharmaceutical products. Among these subsidiaries are CSPC NBP Pharmaceutical Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., and CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Notably, CSPC Zhongnuo is a non-wholly-owned subsidiary, with the Group holding a 99.393% stake. Meanwhile, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., focuses on research and development within the pharmaceutical sector. These subsidiaries, based in the People's Republic of China, play a crucial role in advancing the Group's mission to provide high-quality pharmaceutical products and innovative research solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10